Training Resources

International Diabetes Center

AGP–Ambulatory Glucose Profile

AGP Reports

Selected Literature

Aleppo G. Clinical application of time in range and other metrics. Diabetes Spectr. 2021;34:109-118.

Aleppo G, Webb K. Continuous glucose monitoring integration in clinical practice: a stepped guide to data review and interpretation. J Diabetes Sci Technol. 2019;13:664-673.

American Diabetes Association. 7. Diabetes technology: standards of medical care in diabetes – 2021. Diabetes Care. 2021;44(S1):S85-S99.

Battelino T, et al. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. Diabetes Care. 2019;42:1593-1603.

Beck RW, et al. The relationships between time in range, hyperglycemia metrics, and HbA1C. J Diabetes Sci Technol. 2019;13:614-626.

Beck RW, et al; DIAMOND Study Group. Continuous Glucose Monitoring Versus Usual Care in Patients With Type 2 Diabetes Receiving Multiple Daily Insulin Injections: A Randomized Trial.
Ann Intern Med. 2017 Sep 19;167(6):365-374.

Bergenstal RM, et al. Glucose management indicator (GMI): a new term for estimating A1C from continuous glucose monitoring. Diabetes Care. 2018;41:2275-2280.

Carlson AL, et al. Clinical use of continuous glucose monitoring in adults with type 2 diabetes. Diabetes Technol Ther. 2017;19(Suppl. 2):S4–S11.

Danne T, et al. International consensus on use of continuous glucose monitoring. Diabetes Care. 2017;40:1631-1640.

Ehrhardt NM, et al. The effect of real-time continuous glucose monitoring on glycemic control in patients with type 2 diabetes mellitus. J Diabetes Sci Technol. 2011;5:668-675.

Grunberger G, et al. American Association of Clinical Endocrinology Clinical Practice Guideline: The Use of Advanced Technology in the Management of Persons with Diabetes Mellitus. Endocrine Practice. 2021;27:505-537.

Hack T, et al. Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicenter, open-label randomized controlled trial. Diabetes Ther. 2017;8:55–73.

Kruger DF, et al. Reference guide for integrating continuous glucose monitoring into clinical practice. Diabetes Educ. 2019;45:3S-20S.

Maiorino MI, et al. Effects of Continuous Glucose Monitoring on Metrics of Glycemic Control in Diabetes: A Systematic Review With Meta-analysis of Randomized Controlled Trials. Diabetes Care. 2020 May;43(5):1146-1156.

Martens T, et al. MOBILE Study Group. Effect of Continuous Glucose Monitoring on Glycemic Control in Patients With Type 2 Diabetes Treated With Basal Insulin: A Randomized Clinical Trial. JAMA. 2021 Jun 8;325(22):2262-2272.

Miller EM. Using continuous glucose monitoring in clinical practice. Clin Diabetes. 2020 Dec;38(5):429-438.

Riddlesworth TD, et al. Optimal sampling duration for continuous glucose monitoring to determine long-term glycemic control. Diabetes Technol Ther. 2018;20:314-316.

Ruedy KJ, et al. DIAMOND Study Group. Continuous glucose monitoring in older adults with type 1 and type 2 diabetes using multiple daily injections of insulin: results from the DIAMOND trial. J Diabetes Sci Technol. 2017;11:1138-1146.

Shrivastav M, et al. Type 2 diabetes management in primary care: the role of retrospective, professional continuous glucose monitoring. Diabetes Sprect. 2018;31:279-287.

Siegmund T, et al. Discrepancies Between Blood Glucose and Interstitial Glucose-Technological Artifacts or Physiology: Implications for Selection of the Appropriate Therapeutic Target J Diabetes Sci Technol. 2017;11:766‐772.

Sierra JA, et al. Clinical and economic benefits of professional CGM among people with type 2 diabetes in the united states: analysis of claims and lab data. J Med Econ. 2018;21:225-230.

Wright EE, et al. Use of Flash Continuous Glucose Monitoring Is Associated With A1C Reduction in People With Type 2 Diabetes Treated With Basal Insulin or Noninsulin Therapy. Diabetes Spect. 2021;34:184-189.